DATROWAY® (Datopotamab deruxtecan-dlnk)

The FDA on May 22, 2026, approved DATROWAY® for adult patients with unresectable or metastatic Triple-Negative Breast Cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY® is a product of Daiichi Sankyo, Inc.